TBK/IKKε Inhibitor Compounds Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immunological disorders and cancer related to TBK and IKKε overexpression are inadequate due to the lack of effective inhibitors that can selectively target these serine/threonine kinases, leading to uncontrolled cell proliferation and immune response dysregulation.
Innovation Solution
Development of compounds of Formula (I) that act as dual inhibitors of TBK and IKKε, offering high solubility and bioavailability, which can selectively modulate the activity of these kinases to treat immunological disorders and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for immunological disorders and cancer, then existing therapeutic options are available, but they are inadequate due to lack of effective selective inhibitors targeting TBK and IKKε
Solution Approach 1:
The compound is designed with specific molecular characteristics that enable selective binding to TBK and IKKε kinases. The chemical structure includes functional groups and spatial arrangement that match the active site geometry of these specific kinases, allowing selective inhibition without affecting other kinase family members. This local structural optimization provides the needed selectivity while maintaining therapeutic effectiveness.
Solution Approach 2:
The invention modifies key parameters of kinase inhibitors including molecular weight, solubility, and binding affinity. By optimizing these parameters, the compound achieves both high selectivity for TBK/IKKε and sufficient potency for therapeutic effect. The balanced parameter profile resolves the contradiction between being selective and being effective.
2Measurement precision
If compounds are designed to selectively inhibit TBK and IKKε, then treatment specificity is improved, but developing such selective inhibitors has been unsuccessful to date
Solution Approach 1:
The compound serves multiple functions simultaneously: it selectively binds to TBK and IKKε, maintains adequate solubility for pharmacokinetic performance, and provides sufficient stability for drug development. This multi-functional design approach makes the selective inhibitor practically developable while achieving high targeting specificity.
Solution Approach 2:
The inhibitor combines multiple chemical moieties into a composite molecular structure. This composite design allows the molecule to achieve selective binding through specific interactions while other parts of the molecule contribute to solubility and pharmacokinetic properties, making the selective inhibitor feasible to manufacture and develop.
3Reliability
If compounds of Formula (I) are used as dual inhibitors, then TBK and IKKε activity is effectively inhibited, but the complexity of targeting two highly homologous kinases simultaneously increases
Solution Approach 1:
The compound is designed to target both TBK and IKKε simultaneously through a single molecular entity. By merging the targeting capability for both kinases into one compound, the invention simplifies the therapeutic approach compared to using separate inhibitors, while achieving effective dual inhibition through the shared structural features of these homologous kinases.
Data Source
AI summary
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.